Bolivia vs Bosnia and Herzegovina: Treatment success rate for patients treated for MDR-TB
Bolivia
42.0%
in 2022
Bosnia and Herzegovina
33.0%
in 2022
Bolivia rank
149th
Bosnia and Herzegovina rank
151st
Treatment success rate for patients treated for MDR-TB over time
- Bolivia
- Bosnia and Herzegovina
How they compare
Bolivia currently reports 42.0% against 33.0% in Bosnia and Herzegovina, a difference of 9.0%.
That makes Bolivia's figure about 1.3 times Bosnia and Herzegovina's.
The two have swapped places 5 times across 8 shared years of data; in 2009 it was Bosnia and Herzegovina ahead.
Bolivia ranks 149th and Bosnia and Herzegovina ranks 151st of 163 countries.
Across the 3 decades both report, Bolivia averaged higher in 1 and Bosnia and Herzegovina in 2.
Head to head by decade
| Decade | Bolivia | Bosnia and Herzegovina | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 76.0% | 100.0% | 24.0% | Bosnia and Herzegovina |
| 2010s | 64.2% | 64.5% | 0.3% | Bosnia and Herzegovina |
| 2020s | 42.0% | 33.0% | 9.0% | Bolivia |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher treatment success rate for patients treated for mdr-tb, Bolivia or Bosnia and Herzegovina?
- Bolivia, at 42.0% against 33.0% in Bosnia and Herzegovina as of 2022.
- What is the difference in treatment success rate for patients treated for mdr-tb between Bolivia and Bosnia and Herzegovina?
- 9.0%, with Bolivia ahead.
- How many years of comparable data are there for Bolivia and Bosnia and Herzegovina?
- 8 years are reported by both, from 2009 to 2022.
- How do Bolivia and Bosnia and Herzegovina rank globally for treatment success rate for patients treated for mdr-tb?
- Bolivia ranks 149th and Bosnia and Herzegovina ranks 151st of 163 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Treatment success rate for patients treated for MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.